You are here

myelofibrosis

Ajax, aiming for a better JAK drug, raises $95M to begin first tests

BioPharma Dive

Tue, 05/14/24 - 11:37 am

Ajax Therapeutics

Novartis may have bought MorphoSys, but it really only had eyes for BET inhibitor pelabresib: filing

Fierce Biotech

Fri, 04/12/24 - 11:23 am

MorphoSys’ pelabresib meets endpoints in Phase III myelofibrosis trial

Clinical Trials Arena

Tue, 11/21/23 - 11:55 am

clinical trials

In pleasant surprise for GSK, FDA approves Jakafi challenger Ojjaara in broad blood cancer use

Fierce Pharma

Sun, 09/17/23 - 09:47 pm

Incyte Abandons Phase III Trial for Myelofibrosis Treatment

BioSpace

Mon, 03/6/23 - 11:06 am

clinical trials

GSK explores new avenues for JAK drug in $1.9B Sierra buy amid pending FDA decision

Fierce Biotech

Mon, 12/12/22 - 10:23 am

Sierra Oncology

Galecto links blood cancer prospect to reduced fibrosis in early data drop

Fierce Biotech

Thu, 09/29/22 - 09:51 am

clinical trials

AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Fierce Biotech

Tue, 04/12/22 - 08:31 pm

A new JAK inhibitor earns FDA nod in myelofibrosis, setting up a fight with Incyte, Bristol Myers

Endpoints

Tue, 03/1/22 - 10:35 am

Bristol Myers Squibb

Imago BioSciences Advances Myelofibrosis Trials, With Phase IIb Prelim Readout Imminent

BioSpace

Wed, 06/3/20 - 11:30 pm

clinical trials

Celgene wins approval for drug key to Bristol buyout

Biopharma Dive

Fri, 08/16/19 - 01:06 pm

Bristol-Myers Squibb

Sierra doubles down on ex-Gilead drug, deprioritizes other assets

Fierce Biotech

Fri, 06/28/19 - 12:28 pm

Sierra Oncology

Gilead Sciences

Did Geron's Big Announcement Just Go Unnoticed?

Yahoo/Motley Fool

Thu, 05/16/19 - 06:50 pm

Sierra Oncology Acquires Gilead’s Stalled Myelofibrosis Drug

Xconomy

Wed, 08/22/18 - 05:47 pm

Gilead Sciences

Sierrra Oncology

A Huge Decision Is on Tap for This Little Biotech Stock

Yahoo/Motley Fool

Wed, 05/16/18 - 09:20 am

Four years after it imploded at Sanofi, John Hood is resurrecting the myelofibrosis drug fedratinib

Endpoints

Fri, 10/13/17 - 09:52 am

Impact Biomedicines

Gilead Fails to Beat Incyte’s Jakafi Drug

Investopedia

Sat, 11/19/16 - 11:32 am

Gilead Sciences

Shire bids CTI and its troubled myelofibrosis drug adieu, buying its way out of a deal

Endpoints

Tue, 10/25/16 - 09:54 am

Geron shares jump after two positive drug studies

Marketwatch

Thu, 09/3/15 - 06:33 pm

essential thrombocythemia

ASCO '15: CTI Biopharma Takes on Myelofibrosis Drug Rival

TheStreet.com

Sat, 05/30/15 - 05:44 pm

Pages